Lightowlers M W, Jensen O, Fernandez E, Iriarte J A, Woollard D J, Gauci C G, Jenkins D J, Heath D D
Molecular Parasitology Laboratory, The University of Melbourne, Vic. Australia.
Int J Parasitol. 1999 Apr;29(4):531-4. doi: 10.1016/s0020-7519(99)00003-x.
Experimental vaccine trials against hydatid disease have been undertaken in sheep using the EG95 recombinant vaccine. Challenge infection was with viable Echinococcus granulosus eggs obtained from a New Zealand isolate (dog/sheep cycle), an Australian isolate (dingo/wallaby cycle) and an Argentine isolate (dog/sheep cycle). Vaccination with EG95 conferred a high degree of protection against challenge with all three parasite isolates (protection range 96-100%). Taken together, the trials demonstrated that 86% of vaccinated sheep were completely free of viable hydatid cysts when examined approximately 1 year after challenge infection. Vaccination reduced the number of viable cysts by 99.3% compared with unvaccinated controls. These results suggest that the EG95 vaccine could have wide applicability as a new tool for use in hydatid control campaigns.
已经使用EG95重组疫苗在绵羊身上开展了针对包虫病的实验性疫苗试验。攻毒感染所用的是从新西兰分离株（犬/羊循环）、澳大利亚分离株（澳洲野犬/小袋鼠循环）和阿根廷分离株（犬/羊循环）获得的活细粒棘球绦虫卵。用EG95疫苗接种对所有三种寄生虫分离株的攻毒均提供了高度保护（保护范围为96%-100%）。综合来看，这些试验表明，在攻毒感染后约1年进行检查时，86%的接种疫苗绵羊完全没有活的包虫囊肿。与未接种疫苗的对照相比，接种疫苗使活囊肿数量减少了99.3%。这些结果表明，EG95疫苗作为用于包虫病防治运动的一种新工具可能具有广泛的适用性。
